Diego Díaz-García, Medical Oncologist (CEO) Founder at CánCare – High-Specialty Oncology Care, shared on X:
“HARMONi: Ivonescimab after EGFR-TKI progression.
Ph3 HARMONi evaluated ivonescimab + chemo vs chemo alone in advEGFRmut NSCLC after progression on a 3rdgen EGFR-TKI:
- PFS: 6.8 vs 4.4 months
- HR 0.52 (95% CI, 0.41-0.66; p<0.0001)
- OS: 16.8 vs 14.0 months
- HR 0.79 (95% CI, 0.62-1.01)
A significant PFS benefit, while OS remains less definitive.”
See gallery below
Title: Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Authors: Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Wenting Li, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Lori Styles, Jianling Li, Fong Clow, Jonathan Goldman, Li Zhang.
You can also read ‘50th International Conference on Screening for Lung Cancer and 18th Conference on Research for Early Lung Cancer Treatment‘
